Literature DB >> 12792793

TP53 mutations in primary breast carcinomas from white and African-Brazilian patients.

Maria Aparecida Nagai1, Helenemarie Schaer Barbosa, Marco Antonio Zago, Wilson Araújo Silva, Inês Nobuko Nishimoto, Sibeli Salaorni, Lívia Nery Franco Guerreiro Costa, Marcos Silva Araújo, Ana Gabriela Caldas Oliveira, Mário Mourâo Neto, Maria Mitzi Brentani.   

Abstract

We have attempted to determine the incidence, nature and clinical significance of TP53 mutation in a group of white (242 cases) and African-Brazilian (52 cases) patients with breast cancer. The interethnic admixture as estimated by STR markers showed that white subjects displayed 67.9+/-0.4%, 25.0+/-1.7% and 7.0%+/-1.6% and the black populations had 34.4+/-1.9%, 56.2+/-1.9 and 9.4+/-2.2% respectively of European, African and Amerindian genes. Clinical parameters such as age, lymph node status and steroid receptors were similar in both groups. African-Brazilian patients presented more advanced lesions. Mutation screening was performed using polymerase chain reaction-single strand conformation analysis followed by sequencing. Compared to whites (13.6%), a relatively high frequency of TP53 mutation was found in blacks (32.7%) (p=0.001). African-Brazilian women have a larger proportion of mutations in exons 5 and 7, whereas white women have more mutations in exon 8. Mutations within exon 4 were found only in tumors of white patients. The spectra of TP53 mutations show that A:T-->G:C nucleotide transversion and G:C-->C:G transition were more common in African-Brazilian women whereas G:C-->T:A transversion occurs very frequently in whites. A high prevalence of G:C-->A:T nucleotide transitions and deletions was detected in both groups. No association was found between p53 gene mutation and tumor or clinical parameters independently of the ethnic group. With a median follow-up of 35.6 months for whites and 43.4 months for the blacks, no differences in overall survival were found. If white patients were stratified according to the type and location of TP53 mutations, patients with mutations affecting amino acids directly involved in DNA or Zn binding displayed a poor prognosis. The pattern of mutations found in our population seems to reflect a base line pattern observed in populations with similar ethnic profile with some modifications, which might be derived from specific etiological factors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12792793

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  7 in total

Review 1.  Centrosome amplification: a suspect in breast cancer and racial disparities.

Authors:  Angela Ogden; Padmashree C G Rida; Ritu Aneja
Journal:  Endocr Relat Cancer       Date:  2017-05-17       Impact factor: 5.678

2.  TP53 genetic alterations in Arab breast cancer patients: Novel mutations, pattern and distribution.

Authors:  Abeer J Al-Qasem; Mohamed Toulimat; Abdelmoneim M Eldali; Asma Tulbah; Nujoud Al-Yousef; Sooad K Al-Daihan; Nada Al-Tassan; Taher Al-Tweigeri; Abdelilah Aboussekhra
Journal:  Oncol Lett       Date:  2011-01-18       Impact factor: 2.967

3.  Specific TP53 mutations predict aggressive phenotype in head and neck squamous cell carcinoma: a retrospective archival study.

Authors:  Jenni K Peltonen; Kirsi H Vähäkangas; Henni M Helppi; Risto Bloigu; Paavo Pääkkö; Taina Turpeenniemi-Hujanen
Journal:  Head Neck Oncol       Date:  2011-04-22

4.  TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases.

Authors:  Chi Young Ok; Keyur P Patel; Guillermo Garcia-Manero; Mark J Routbort; Jie Peng; Guilin Tang; Maitrayee Goswami; Ken H Young; Rajesh Singh; L Jeffrey Medeiros; Hagop M Kantarjian; Rajyalakshmi Luthra; Sa A Wang
Journal:  J Hematol Oncol       Date:  2015-05-08       Impact factor: 17.388

5.  Combined Antiangiogenic and Mammalian Target of Rapamycin Inhibitor Targeted Therapy in Metaplastic Breast Cancer Harboring a PIK3CA Mutation.

Authors:  Rishi Agarwal; Kimberly Koenig; Eric Rohren; Vivek Subbiah
Journal:  J Breast Cancer       Date:  2014-09-30       Impact factor: 3.588

6.  PIK3CA exon 20 mutations are associated with poor prognosis in breast cancer patients.

Authors:  Flavia R Mangone; Irina G Bobrovnitchaia; Sibeli Salaorni; Erika Manuli; Maria A Nagai
Journal:  Clinics (Sao Paulo)       Date:  2012-11       Impact factor: 2.365

7.  An identical, complex TP53 mutation arising independently in two unrelated families with diverse cancer profiles: the complexity of interpreting cancer risk in carriers.

Authors:  E M Pinto; R C Ribeiro; J Li; L Taja-Chayeb; L F Carrasco; M de Lourdes Peña-Torres; S Vidal-Millán; H Maldonado-Mtz; A Dueñas-González; L McGregor; G P Zambetti
Journal:  Oncogenesis       Date:  2012-02-20       Impact factor: 7.485

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.